Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17563243 | 0.87 | PNMT (0.38) | ALDH1A1GAATRIM24 | |
| SCHEMBL12698059 | 0.78 | POLB (0.41) | HTT | |
| SCHEMBL13091165 | 0.76 | HSD17B10 (0.40) | ALDH1A1GAAPKMHTTMEN1 | |
| SCHEMBL31714457 | 0.75 | LMNA (0.45) | ALDH1A1GAABRD4LMNA | |
| SCHEMBL10076590 | 0.74 | DRD2 (0.52) | ALDH1A1GAATRIM24PKMBRD4 | |
| SCHEMBL31714699 | 0.73 | CASP1 (0.49) | ALDH1A1GAAHTTMEN1KMT2A | |
| SCHEMBL15833728 | 0.73 | PDE3B (0.47) | HTTMEN1KMT2A | |
| SCHEMBL30434996 | 0.73 | PDE3B (0.47) | HTTMEN1KMT2A | |
| SCHEMBL10075473 | 0.72 | PKM (0.61) | ALDH1A1GAATRIM24PKMBRD4 | |
| SCHEMBL5423529 | 0.71 | MAOA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | PDK2, PDK1, PDK3 | ALDH1A1 1184/4885GAA 2394/4885TRIM24 3384/4885 |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | PDK1, PDK2, PCK1 | ALDH1A1 1936/4885GAA 846/4885TRIM24 2883/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | ALDH1A1 1010/4885GAA 565/4885TRIM24 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.